According to AstraZeneca's latest financial reports the company has A$7.74 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | A$8.60 B | -6.24% |
2022-12-31 | A$9.17 B | 3.95% |
2021-12-31 | A$8.82 B | -15.09% |
2020-12-31 | A$10.39 B | 17.05% |
2019-12-31 | A$8.87 B | 11.82% |
2018-12-31 | A$7.94 B | 36.13% |
2017-12-31 | A$5.83 B | -27.64% |
2016-12-31 | A$8.06 B | -12.91% |
2015-12-31 | A$9.25 B | 7.59% |
2014-12-31 | A$8.60 B | -22.44% |
2013-12-31 | A$11.09 B | 40.18% |
2012-12-31 | A$7.91 B | -28.05% |
2011-12-31 | A$10.99 B | -5.53% |
2010-12-31 | A$11.64 B | -8.28% |
2009-12-31 | A$12.69 B | 103.94% |
2008-12-31 | A$6.22 B | -8.67% |
2007-12-31 | A$6.81 B | -30.09% |
2006-12-31 | A$9.74 B | 43.25% |
2005-12-31 | A$6.80 B | 0.02% |
2004-12-31 | A$6.80 B | 28% |
2003-12-31 | A$5.31 B | -36.12% |
2002-12-31 | A$8.32 B | 11.08% |
2001-12-31 | A$7.49 B | -5.93% |
2000-12-31 | A$7.96 B | 59.15% |
1999-12-31 | A$5.00 B | -10.21% |
1998-12-31 | A$5.57 B | 201.25% |
1997-12-31 | A$1.84 B | -11.99% |
1996-12-31 | A$2.10 B |